phathom-pharmaceuticals-logo.jpg
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
29 août 2024 08h00 HE | Phathom Pharmaceuticals
FLORHAM PARK, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for...
wuFVh3u3_400x400.jpg
Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025
29 août 2024 07h30 HE | Big4Bio
New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week
Chase Hall, M.D., as Chief Medical Advisor
Appointment of Chase Hall, M.D., as Chief Medical Advisor
28 août 2024 09h01 HE | Polarean
DURHAM, NC and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
28 août 2024 08h00 HE | Vor Biopharma
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
Captura de pantalla 2023-11-10 082355 big.png
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
27 août 2024 08h00 HE | Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
redalpine +.png
redalpine closes largest fund to date, $200M RAC VII, and announces new London office
27 août 2024 08h00 HE | Redalpine
Zurich, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Leading European venture capital firm redalpine today announced the final close of its largest-ever fund, redalpine capital VII (RAC VII), at $200M....
Cellectis Logo.png
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
26 août 2024 16h30 HE | Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Madrigal logo.jpg
Madrigal Pharmaceuticals, Inc. to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
26 août 2024 08h00 HE | Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global...
Logo.png
Halberd Corp. Issues Letter to Shareholders
26 août 2024 08h00 HE | Halberd Corp.
Halberd Corp. - Taking a Moment to Recenter Our Technical Progress
Regeneron Logo.jpg
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
26 août 2024 01h00 HE | Regeneron Pharmaceuticals, Inc.
20 abstracts, including 4 oral presentations, offer new treatment insights for chronic obstructive pulmonary disease (COPD), asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) Data from...